Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice

Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity profile of CPI compared with chemotherapy, oncologists may have a low threshold to prescribe CPI to patients near the end of life. We evaluat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Parikh, Ravi B., Galsky, Matthew D., Gyawali, Bishal, Riaz, Fauzia, Kaufmann, Tara L., Cohen, Aaron B., Adamson, Blythe J.S., Gross, Cary P., Meropol, Neal J., Mamtani, Ronac
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Brief Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656487/
https://ncbi.nlm.nih.gov/pubmed/30944183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados